Southern Finance and Economics, September 27th - Sanofi announced that Dabitou& reg; Dupilumab injection has been approved by the National Medical Products Administration (NMPA) of China for use in adult patients with chronic obstructive pulmonary disease who have elevated blood eosinophils and poor control. This approval was granted prior to the FDA approval in the United States, and compared to the European Union and the United States, China has the shortest approval time, once again breaking the record for innovative drugs benefiting Chinese patients. Dabitou& reg; It is the world's first approved targeted therapy drug for chronic obstructive pulmonary disease. (21st Century Business Herald)